OVERVIEW

Homeopathic treatment for premenstrual symptoms

Angela Jones, DFFP, MFHom, General Practitioner and Medical Director, Luther Street Medical Centre, Oxford, UK

Correspondence: Dr A M Jones, Luther Street Medical Centre, PO Box 7, St Aldates, Oxford OX1 1TD, UK. Tel: +44 (0) 1865 726008. Fax: +44 (0) 1865 204133. E-mail: angela.jones@doctors.org.uk

(Accepted 1st November 2002)

Journal of Family Planning and Reproductive Health Care 2002; **29**(1): 25–28

Abstract

Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) are well-documented disorders causing significant morbidity in the female population. Treatments prescribed do not necessarily reflect proven clinical effectiveness. A recent systematic review from the Exeter Department of Complementary Medicine failed to endorse complementary therapies as a whole for treatment of PMS. However, a recent randomised controlled trial of homeopathic treatment for PMS confirms the clinical experience of homeopathic physicians that homeopathy is helpful in PMS.

Key message points

- Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) cause significant morbidity in the female population.
- Homeopathy relies on detailed analysis of symptomatology to identify a medicine with matching characteristics.
- Homeopathic physicians have reported anecdotally that homeopathic treatments for PMS are helpful.
- A randomised, controlled double-blind trial published in 2001 has confirmed the positive outcome of the previous anecdotal experience.
- Many women are interested in complementary therapies and therefore an understanding of the possible role of homeopathy in the management of PMS is important.

Introduction

Premenstrual syndrome (PMS) describes a constellation of symptoms that occur during the late luteal phase of the menstrual cycle and remit after the menses. These include generalised fluid retention, sensation of abdominal bloating, breast enlargement and breast tenderness plus mood disturbance and food cravings. When the mood disturbances (depressed mood, tension, labile affect, irritability, reduced impulse control) are severe, the syndrome is designated as premenstrual dysphoric disorder (PMDD).

Up to 75% of women report some premenstrual symptoms with approximately 10% suffering PMDD.¹ A recently published survey of UK prescribing data for PMS between 1993 and 1998² showed a general decrease in prescribing for this diagnosis, with progestogens, including progesterone, being the most widely prescribed, despite the lack of evidence demonstrating their efficacy. Selective serotonin re-uptake inhibitors (SSRIs), which were licensed for severe PMS/PMDD during this period, were the second most popular prescription. Vitamin B6 prescriptions dropped markedly, probably as a result of government recommendations on reduction of dosage.

There is also a whole range of physical illnesses that are known to be affected by the menstrual cycle in females. Menstrual cycle-related exacerbation of conditions such as migraine, diabetes, asthma, epilepsy and irritable bowel syndrome (IBS) are well-recognised^{3,4} and various

therapeutic manipulations have been suggested, although none seem to have been the subject of definitive research.

Use of complementary therapies

Complementary therapies have been popular historically with women suffering from premenstrual symptoms. This is unsurprising given that until the introduction of the SSRIs, the only 'conventional' treatments were hormonal and, in the case of the progestogens, were not especially efficacious. A systematic review of the use of complementary therapies for premenstrual syndrome was published in 2001 by Stevinson and Ernst.⁵ Among the papers reviewed was one on homeopathy. The authors acknowledged some positive findings but found the evidence insufficiently 'compelling' to recommend any of the therapies.

However, in the same month, Yakir et al. published a pilot study on the effects of homeopathic treatment in women with PMS.⁶ This was a randomised, controlled, double-blind clinical trial. Twenty women from 20 to 48 years of age received individualised homeopathic treatment or placebo and their symptoms were scored using a daily menstrual distress questionnaire. Improvement of greater than 30% was observed in 90% of patients receiving active treatment and 37.5% receiving placebo ($p = 0.048$). Although this trial probably needs to be repeated with larger numbers to improve its power, it is certainly encouraging and confirms the clinical impression gained by hundreds of medically qualified homeopathic physicians who find that homeopathy is a useful therapeutic approach for PMS.

What is homeopathy?

Homeopathy is a system of therapy that relies on a detailed analysis of an individual patient's symptomatology in order to identify a medicine with matching characteristics. If this medicine is then given in minute doses, it is said to act as a stimulus to the body's own healing processes and to eliminate the symptoms, and hence the disorder. As a therapeutic system it has been used for over 200 years. Indeed, until the advent of modern 'scientific' medicine, homeopathy was threatening to supersede the conventional treatments of the 19th and early 20th centuries both in Britain, Europe and the USA.⁷ Although it can never have the often overwhelming chemical effects of modern pharmacotherapy, homeopathy is still valued by both patients, and the physicians who use it, for its ability to address many illnesses and symptom complexes for which there is no answer in the standard formularies. In the UK, several hundred doctors hold qualifications in homeopathic medicine from the Faculty of Homeopathy, which oversees the training and examination of statutorily qualified health professionals in homeopathy.

Homeopathy and PMS/PMDD

In textbooks describing the symptoms for which each homeopathic medicine is effective, the so-called 'materia medica', it is remarkable to find that all homeopathic medicines are described to relate to symptoms in many systems of the body, both physical and psychological. Thus it is possible to find, for instance, a medicine for headaches before menses, a distended abdomen before menses and great tearfulness before periods which responds to being comforted. The homeopathic medicine, Pulsatilla, is derived from the pasque flower, *Pulsatilla nigricans*. Conversely, the pattern of back pain before periods, cramping abdominal pains and a raging temper such that the woman feels as if she wants to stab someone (usually her partner) would be addressed by the medicine, Nux vomica, derived from the so-called marking nut, *Strychnos nux vomica*. Another well-known picture is that of increasing weariness and irritability before periods, accompanied by a desire to be left alone. This kind of subject usually suffers from a dragging low backache and, when the period finally arrives, it is often accompanied by dragging pains as if the womb is prolapsing. This symptom complex responds to the homeopathic medicine, Sepia, derived from the ink of the cuttlefish, *Sepia officinalis*.

Another important factor in deciding on a homeopathic medicine is how quickly the PMS symptoms settle after the onset of menstruation. In the case of Sepia, the symptoms usually last a few days into the period, before gradually dissipating. With Nux vomica, they may last a little longer. However, if a patient describes a PMS symptom complex that settles immediately at the onset of bleeding, the physician should consider prescribing Lachesis, derived

from the venom of a South American snake. This medicine has the characteristic that it acts on symptoms that are improved by a 'discharge' of any kind, of which menstrual bleeding is an example.

Once the homeopathic physician has chosen the most suitable medicine, it is then usually taken over a few days at mid-cycle. If, by this method, the premenstrual symptoms are eliminated, it is possible to stop taking the medicine. It will often be a number of months, or even years, before the symptoms return. If the returning symptoms are identical to before, further doses of the same medicine can be taken until benefit is achieved. However, if the symptom complex has altered, then it is only logical that a different medicine, one that matches the new picture, will have to be chosen.

Finally, homeopathic treatment is well placed to address some of the more mysterious complaints such as premenstrual migraine, asthma, epilepsy and IBS. Medicines are recognised which can help with any of these complaints, specifically with a premenstrual aggravation. For instance, homeopathically prepared Sulphur or Zinc may be useful in the case of bronchial hypersensitivity, Cuprum (copper) and Pulsatilla (among others) are named as having an effect in convulsions before menses, and for premenstrual IBS, Nux vomica again, or Colocynthis (the bitter cucumber) or indeed one of 40 or 50 medicines listed may be prescribed.

It is worth knowing that the UK National Health Service funds prescription of homeopathic medicines and general practitioners and hospital doctors alike can prescribe on the usual prescription forms. Given the low cost of these medicines, and the fact that a long-term prescription is often not required, this method of management of PMS/PMDD

Just imagine if every time a young woman forgot to take her Cilest® oral contraceptive pill, she turned up at your surgery for advice. Without the Cilest® Helpline, that's just what might have happened.

We've offered support and advice to over ½ million callers since the Helpline's launch – it's no wonder that so many doctors and young women have come to rely on Cilest®

Cilest®

norgestimate and ethinyloestradiol

A pill you and your patients can feel at ease with

Cilest® (norgestimate and ethinyloestradiol). Abbreviated Prescribing Information. (Please refer to Summary of Product Characteristics (SPC) before prescribing). **Presentation:** Calendar pack of 21 tablets each containing 0.25 mg norgestimate and 35 µg ethinyloestradiol. **Uses:** Oral contraception. **Dosage:** One tablet daily for 21 days followed by 7 tablet-free days. **Contra-indications, warnings and precautions:** For full details see SPC. **Contra-indications:** Pregnancy or suspected pregnancy. Past or present circulatory disorders, moderate to severe hypertension, hyperlipoproteinaemia. Presence of more than one recognised risk factor for arterial disease. Past or present severe liver disease, history of jaundice during pregnancy or due to the use of steroids, Rotor and Dubin-Johnson syndromes and porphyria. Cholelithiasis. Known or suspected oestrogen-dependent tumours, endometrial hyperplasia or undiagnosed vaginal bleeding. Past or present SLE. History, during pregnancy or previous use of steroids, of severe pruritus, herpes gestationis, manifestation or

deterioration of osteoporosis. **Relative contra-indications:** Risk of circulatory or thrombo-embolic disorder, history of cholelithiasis, presence/history of epilepsy, migraine, severe depression, stable cell haemoglobinopathy. Presence of any risk factors for oestrogen-dependent tumours or oestrogen-sensitive gynaecological disorders. Diabetes mellitus. Discontinue use if above appear or are aggravated or if liver function tests become abnormal. **Precautions and warnings:** Cholestasis. Examinations and investigations at start, then as deemed clinically appropriate. Post-partum administration. Breast feeding. Changing from combined ED or POP. Reliability of oral contraceptives may be reduced under the following circumstances: forgotten tablets, vomiting or diarrhoea, change in bleed pattern after several months, drug interactions (including OTC/herbal products). Surgery, varicose veins, immobilisation. **Adverse reactions:** Most commonly reported in early cycles of oral contraceptive therapy include breakthrough bleeding, spotting, nausea, vomiting and other GI disturbances. Other

side effects may include breast changes, metabolic changes, epidermal changes, CNS disturbances, hypertension and corneal discomfort if contact lenses are used. **Rarely:** thromboembolic events, sex steroid-dependent tumours, liver disease, SLE, cholestasis. Possible increased risk of breast cancer should be discussed with user and weighed against benefits of taking COCs (see SPC for details). **Package quantities:** 3 and 6 blister strips of 21 tablets. **Price:** £6.42 per 3 x 21 tablets; £12.84 per 6 x 21 tablets. **Product licence number:** 0242/0209. **Product licence holder:** Janssen-Cilag Ltd, Sanderson, High Wycombe, Buckinghamshire HP14 4HU, UK. Further information available from Janssen-Cilag Ltd, Sanderson, High Wycombe, Buckinghamshire HP14 4HU UK. **Legal category:** POM. **APPROVED FOR SALE.** **References:** 1. Janssen-Cilag, data on file. Report prepared from TMM. **Date of preparation:** December 2002. 03336

should be very cost effective in comparison with recurrent courses of hormones or SSRIs.

Case studies

Case 1

History: A 42-year-old woman, married with two teenage children. Presented with increasing mental distress before periods. Marked forgetfulness; had driven away from school gate without picking up children on more than one occasion. Increasing depression and feeling of hopelessness for last 6 months, always relieved within hours of period starting 'as if a huge weight was being lifted'. Also physical symptoms, in particular marked breast tenderness such that had to hold breasts when walking. Had resorted to old-fashioned binding of breasts in order to ease the pain. Low abdominal pain, alternating sides from month to month (probably ovarian). Heavy periods, cycle getting shorter (now 22 days). Had tried progesterone therapy for 6 months with no benefit. Evening primrose oil improved breast pain by about 25%.

Treatment: Lac caninum given as a daily dose on Days 8, 9 and 10 (short cycle).

Outcome: Great improvement in all aspects after the first month of treatment. Stopped after 3 months. Recurrence 6 months later, treated straight away. Symptom-free thereafter for over 12 months. Stopped evening primrose oil with no ill effects.

Case 2

History: A 25-year-old clerk in building society, single. Presented with mood disturbance prior to periods. Irritable, moody, outbreaks of acne, from Day 21 until 3 days into

menses. Causing difficulty at work, in that she had found it difficult to cope with colleagues and customers premenstrually. Had purchased vitamin B6 and evening primrose oil but no significant benefit. Not keen on hormonal manipulation in view of strong family history of thrombosis.

Treatment: Sepia given as a daily dose on Days 12, 13 and 14 for three cycles.

Outcome: No response.

Reassessment: Additional symptoms elicited. Sensation of 'water retention' also a feature; mood disturbance was predominantly brooding resentment of everyone around her leading to irritability and low mood; often cried when alone in the evenings; headaches and low backache also occurred at this time; skin generally greasy but acne only breaks out premenstrually.

Treatment: Natrum muriaticum given as a daily dose on Days 12, 13 and 14 for three cycles.

Outcome: Gradual improvement in mood, skin, headache and backache over the 3 months. Treatment prescribed for the next three cycles. At review, asymptomatic. Treatment discontinued and has not had to be repeated.

Conclusions

Homeopathy is one of the 'big five' established complementary therapies as recognised by the British Medical Association in its groundbreaking report on complementary therapies in 1993. Practitioners of homeopathic medicine find that it is an effective approach for the treatment of PMS. A recent pilot randomised controlled trial showed positive findings for homeopathic treatment in PMS and further research is in progress.

Over the past few years, only one pill has offered you this level of support

Acknowledgements

The author would like to thank the Faculty of Homeopathy for its professional support of herself and all homeopathic physicians. She would also like to acknowledge the Hom-Inform Library at Glasgow Homeopathic Hospital for the ongoing development of its online search resource for homeopathic literature.

Statements on funding and competing interests

Funding. None identified.

Competing interests. None identified.

References

- 1 Elliott H. Premenstrual dysphoric disorder. A guide for the treating clinician. *N C Med J* 2002; **63**: 72–75.
- 2 Wyatt KM, Dimmock PW, Frischer M, et al. Prescribing patterns in premenstrual syndrome. *BMC Womens Health* 2002; **2**: 4.
- 3 Tan KS. Premenstrual asthma: epidemiology, pathogenesis and treatment. *Drugs* 2001; **61**: 2079–2086.
- 4 Case AM, Reid RL. Menstrual cycle effects on common medical conditions. *Compr Ther* 2001; **27**: 65–71.
- 5 Stevinson C, Ernst E. Complementary/alternative therapies for premenstrual syndrome: a systematic review of randomised controlled trials. *Am J Obstet Gynecol* 2001; **185**: 227–235.
- 6 Yakir M, Kreitler S, Brzezinski A, et al. Effects of homeopathic treatment in women with premenstrual syndrome: a pilot study. *Br Homeopath J* 2001; **90**: 148–153.
- 7 Nicholls PA. *Homeopathy and the medical profession*. London: Croom Helm, 1988.
- 8 British Medical Association. *Complementary medicine: new approaches to good practice*. New York, NY: Oxford University Press, 1993.

Contact Information: The Faculty of Homeopathy, 15 Clerkenwell Close, London EC1R 0AA, UK. Tel: +44 (0) 171 566 7810. Fax: +44 (0) 171 566 7815. www.truathomeopathy.org

advertisement

TWO NEW PRODUCTS INTRODUCED TO COMPLETE THE FEMSEVEN RANGE

Merck Pharmaceuticals, manufacturer of the Fem Seven (estradiol) range of Hormone Replacement Therapy transdermal patches, has launched two new products into the range. The addition of Fem Seven Sequi (estradiol, estradiol/levonorgestrel), a sequential combined HRT patch, and Fem Seven Conti (estradiol, estradiol/levonorgestrel), a continuous combined HRT patch, to the current Fem Seven unopposed oestrogen patches, will create the world's first complete range of 7-day once-weekly HRT patches.

Products in the Fem Seven range are indicated for oestrogen deficiency symptoms in menopausal women with and without a uterus. The levonorgestrel dose in Fem Seven Conti and Sequi also protects against estradiol-induced risk of endometrial hyperplasia and carcinoma. The competitively priced range was developed because most women prefer to change their patch once every seven days. Most other HRT patches need changing twice-weekly.

For further information please contact
Merck Pharmaceuticals 01895 452251

SERVICE DELIVERY

Can the Internet be used to improve sexual health awareness in web-wise young people?

P C Goold, MB BS, MRCP, *Specialist Registrar in Genitourinary Medicine (GUM), Department of GUM, Nottingham City Hospital NHS Trust, Nottingham, UK*; **M Ward**, RGN, *Health Advisor in GUM, Department of GUM, King's Mill Hospital, Sherwood Forest Hospitals NHS Trust, Sutton in Ashfield, UK*; **E M Carlin**, MB ChB, FRCP, *Consultant in GUM, Department of GUM, Nottingham City Hospital NHS Trust, Nottingham, UK and Department of GUM, King's Mill Hospital, Sherwood Forest Hospitals NHS Trust, Sutton in Ashfield, UK*

Correspondence: Dr P C Goold, Department of Genitourinary Medicine, Nottingham City Hospital NHS Trust, Hucknall Road, Nottingham NG5 1PB, UK. Tel: +44 (0) 115 969 1169 ext 46746. Fax: +44 (0) 115 962 7684. E-mail: pennygoold@aol.com

(Accepted 14th November 2002)

Journal of Family Planning and Reproductive Health Care 2003; **29**(1): 28–30

Abstract

Objectives. To assess Internet use amongst young people to determine whether it would be a practical way to provide sex education and information.

Methods. Year 10 students (aged 14–15 years) from North Nottinghamshire schools were asked to participate in focus groups to discuss the Internet. A series of predefined questions were directed to the whole group to generate debate. Areas explored included: Internet access and site; frequency and purpose of Internet use; websites visited; ideas

for a genitourinary medicine (GUM) website. Responses were recorded by a hand count or as individual verbal responses.

Results. Thirteen focus groups were held involving 287 students of approximately equal sex distribution. All had access to Internet facilities at school and 224 (78.0%) had access elsewhere. Access was at least once a week by 178 (62.0%) mostly for e-mail, games, chatlines and homework. No one accessed for health information. One hundred and seventy-nine (62.4%) participants said they would use a GUM website. A 'question line' where they could e-mail